Predictive Value of the CURB-65, MuLBSTA, Pneumonia Severity Index Scores and Laboratory Parameters for In-Hospital Mortality in Patients with Diabetes Mellitus and COVID-19 Infection.

Publication date: Jul 10, 2026

Background/Objectives: Several risk factors have been identified as being involved in the progression of COVID-19 over time. Among these, age, comorbidities, and various laboratory parameters have been reported. Diabetes mellitus is one of the most common comorbidities found among patients diagnosed with SARS-CoV-2 infection. Glucose metabolism dysfunction can exacerbate pre-existing diabetes or even induce diabetes mellitus. The purpose of this study is to assess the accuracy of the CURB-65, PSI, MuLBSTA severity scores and laboratory parameters in patients with diabetes mellitus diagnosed with COVID-19. Methods: We conducted a retrospective study involving patients with diabetes mellitus diagnosed with SARS-CoV-2 infection, performed between June 2023 and December 2024. Results: We analyzed 73 patients with pre-existing diabetes who were diagnosed with COVID-19. There were 56. 16% men, living mostly in urban areas, with a median hospital stay of 9. 38 days. Elevated levels of LDH (367. 50, p = 0. 002), CRP (133. 90, p = 0. 012), ferritin (724. 25, p = 0. 012), ESR (55. 00, p = 0. 014), D-dimers (2455. 04, p = 0. 004), white blood cells (12. 76, p = 0. 007) and the neutrophil-to-lymphocyte ratio (15. 86, p = 0. 021) were recorded in the group of deceased patients. Significantly elevated values were recorded for all three severity scores, the AUC for CURB-65 was 0. 69, PSI 0. 81 and MuLBSTA 0. 86. Conclusions: Severity scores showed robust prognostic value in predicting mortality among patients with diabetes mellitus and COVID-19, emphasizing their relevance as clinically applicable tools for risk stratification and outcome assessment.

Semantics

Original Article